Longboard Pharmaceuticals clinical trials

Acquired by H. Lundbeck A/S, Dec 2, 2024 · source ↗

The registry lists 6 studies whose lead sponsor is Longboard Pharmaceuticals. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 27, 2026.

Before and after it joined H. Lundbeck A/S

First submitted before Longboard Pharmaceuticals became part of H. Lundbeck A/S: 4
First submitted after Longboard Pharmaceuticals became part of H. Lundbeck A/S: 1
Unclear, or no submission date: 1

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 2
Active, not recruiting: 2
Available: 1
Enrolling by invitation: 1

Phase

Phase 3: 3
Phase 2: 2
Phase 1: 1

Where

Australia: 6
United States: 6
Japan: 3
Italy: 3
Portugal: 3
Serbia: 3

Registry sponsor names on this page

Longboard Pharmaceuticals6 studies

Something wrong with this grouping? Tell us on the H. Lundbeck A/S page.

Studies

Recruiting first, then most recently updated. Showing 6 of 6. All H. Lundbeck A/S studies →

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)Enrolling by invitationNCT06908226Phase 3
Sponsor listed in the registry: Longboard Pharmaceuticals · First submitted after Longboard Pharmaceuticals became part of H. Lundbeck A/S
Intermediate-Size Expanded Access Protocol (EAP) for LP352AvailableNCT06149663
Sponsor listed in the registry: Longboard Pharmaceuticals · First submitted before Longboard Pharmaceuticals became part of H. Lundbeck A/S
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Active, not recruitingNCT06660394Phase 3
Sponsor listed in the registry: Longboard Pharmaceuticals · First submitted before Longboard Pharmaceuticals became part of H. Lundbeck A/S
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)Active, not recruitingNCT06719141Phase 3
Sponsor listed in the registry: Longboard Pharmaceuticals · First submitted the day Longboard Pharmaceuticals became part of H. Lundbeck A/S
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic EncephalopathyCompletedNCT05626634Phase 2
Sponsor listed in the registry: Longboard Pharmaceuticals · First submitted before Longboard Pharmaceuticals became part of H. Lundbeck A/S
Study to Investigate LP352 in Subjects With Developmental and Epileptic EncephalopathiesCompletedNCT05364021Phase 1/2
Sponsor listed in the registry: Longboard Pharmaceuticals · First submitted before Longboard Pharmaceuticals became part of H. Lundbeck A/S